Beyond 2015, Emergent looks to be in a good position to ramp manufacturing of BioThrax. In February, the biotech said that the BioThrax produced in its new Building 55 is comparable to the drug made in its current manufacturing facility. The company just needs the FDA to sign off on the change in manufacturing locations, which should occur later this year or early next year.